Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Relation to biochemical assay, disease-free survival, and clinical endocrine response.
A new immunocytochemical assay for progesterone receptor (PgR-ICA) employing the monoclonal antibody JZB 39 was used to study tumors from two series of patients with breast cancer. In Series 1 assay results were in agreement with those of biochemistry in 76% of 338 cases (P less than 0.001) and in 54% of 101 cases in Series 2 (P less than 0.001). Agreement was better in Series 1 because it included fresher, previously untouched specimens. There were 70 patients in Series 1 with known clinical endocrine response. A negative assay correlated with disease progression in 45 of 57 patients, significantly better than with biochemistry (P = 0.013). In comparing 39 women with rapid disease progression with 39 free of disease at 5.1 years, those with PgR-ICA-positive tumors were over four times more likely to remain disease-free than those with negative results (P = 0.007). Product moment life-table analysis of 79 patients from Series 2 showed a significantly better cumulative survival for those with PgR-ICA-positive tumors (P = 0.047). These findings indicate that PgR-ICA should be of value in planning therapy and predicting disease course in breast cancer patients.
Pertschuk
L P
LP
Department of Pathology, State University of New York, Brooklyn.
Feldman
J G
JG
Eisenberg
K B
KB
Carter
A C
AC
Thelmo
W L
WL
Cruz
W P
WP
Thorpe
S M
SM
Christensen
I J
IJ
Rasmussen
B B
BB
Rose
C
C
D000911:Antibodies, Monoclonal; D001943:Breast Neoplasms / Q000032:analysis*; D002467:Cell Nucleus / Q000032:analysis; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D011980:Receptors, Progesterone / Q000032:analysis*; D012044:Regression Analysis
D000911:Antibodies, Monoclonal; D011980:Receptors, Progesterone